Choroidal neovascularization (CNV) is one of the most important vision-threatening complications secondary to pathological myopia (PM). In the last 20 years, there have been rapid advances in the treatment options for myopic CNV. The aim of this article is to give an overview of several modalities of treatment of CNV in myopes, including laser photocoagulation, transpupillary thermotherapy, radiotherapy, photodynamic therapy with verteporfin and surgical treatments. Based on the scientific progress achieved in the past few years, it is possible that patients with myopic macular degeneration complicated by CNV may benefit from a new ophthalmic frontier of pharmacologic therapy, including intravitreal injections of anti-VEGF drugs. The current status of these novel therapeutic agents is also discussed.